

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



InnoScience (Suzhou) Technology Holding Co., Ltd.

英諾賽科(蘇州)科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2577)

**VOLUNTARY ANNOUNCEMENT
PROGRESS ON THE LAWSUIT WITH INFINEON**

This announcement is made by InnoScience (Suzhou) Technology Holding Co., Ltd. (the “**Company**” or “**InnoScience**”) on a voluntary basis.

The board of directors of the Company is pleased to announce the Company’s victory in its lawsuit with Infineon. On December 02, 2025, U.S. Eastern Time, the U.S. International Trade Commission (the “**ITC**”) issued a ruling in the Section 337 investigation initiated by Infineon against InnoScience. With respect to the two patents involved, the ITC ruled that InnoScience did not infringe on one of the patents at all, and that InnoScience’s workaround design (the design solution currently used in its products) did not infringe on the other patent at all.

This ruling by the ITC further clarifies the status of InnoScience’s relevant intellectual property and will clear the way for its future global development. The Company will continue to respect and protect intellectual property rights and is committed to providing excellent GaN-on-silicon power solutions for global customers.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
InnoScience (Suzhou) Technology Holding Co., Ltd.
英諾賽科(蘇州)科技股份有限公司
Dr. Weiwei Luo
Chairperson of the Board and Executive Director

PRC, December 03, 2025

As at the date of this announcement, the Board of the Company comprises Dr. Weiwei Luo, Mr. Jay Hyung Son, Dr. Wu Jingang and Mr. Zhong Shan as executive directors; Dr. Wang Can, Ms. Zhang Yanhong and Ms. Cui Mizi as non-executive directors; and Mr. Wong Hin Wing, MH, JP, Dr. Yi Jiming, Dr. Yang, Simon Shi-Ning and Dr. Chan, Philip Ching Ho as independent non-executive directors.